• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Spotlight on Aeginition Hospital Athens

2019-12-18News

This month, we get to know the Aeginition Hospital (Athens, Greece) centre behind EPAD. The team of Nikolaos Scarmeas (principal investigator of the EPAD project in Aeginition Hospital) began recruiting in September 2019 and has currently recruited 14 participants in the EPAD Longitudinal Cohort Study (LCS). We caught up with his team and asked them a few questions about their best practices and recruitment strategies.

Any top tips for running the LCS efficiently at your site? We invest a lot of time and effort in communicating with possible EPAD candidates, explaining them in detail the procedures of EPAD and the importance of their role in research activities. Furthermore we work closely with our colleagues in other sections of the hospital so that we make sure that we schedule all the appointments included in each visit (e.g. neuropsychological assessment, sample collection, brain imaging) taking into consideration each participant’s daily routine and special needs. In other words, we show a lot of flexibility (i.e. duration, timing and number of visits) towards accommodating participants’ schedules. We believe that this has helped us increase the engagement of our participants, bearing in mind that we also have volunteers coming from regions not of immediate proximity to our centre.

How are you able to find suitable subjects for the cohort? The main source of eligible EPAD participants is the Cognitive Disorders Clinic of Aeginition Hospital. There is only a single Medical School in Athens (that of the National and Kapodistrian University of Athens – NKUA) and Aeginition is the University Hospital for Neurology and Psychiatry of the NKUA. Every year we thoroughly evaluate more than 300 people, some of which are diagnosed with either subjective cognitive complaints or mild cognitive impairment, and are interested in participating in research projects on Alzheimer’s disease (AD). Moreover, we run another observational study, the Aeginition Longitudinal Biomarker Investigation Of Neurodegeneration (ALBION) aiming towards increasing understanding of the preclinical and prodromal stages of AD. Except from the medical and neuropsychological examination, we further collect bio-samples and run laboratory tests for all participants of ALBION. Thus we are able to find participants with ApoE and amyloid brain pathology that match the EPAD eligibility criteria. Furthermore two additional activities have helped us in finding suitable participants: a) close collaboration with the Non Governmental Organization Athens Alzheimer Association which runs Day Care Centers and Memory clinic services all over Athens and b) participation in medical and neurological conferences where we inform health professionals regarding our research activities.

Any past or future events/conference which have been beneficial for recruitment into EPAD? We have announced our research activities in the National Neurological Conferences, as well as in the local and National conferences on dementia themes. We have also been informing the general public in talks and presentations for lay audience.  We intend to continue to do so as the EPAD activities continue to evolve. We are also in the process of groundwork towards strengthening our network with the public primary care centres in our region.

Any activities in terms of participant engagement? Regarding the research participants that have already been enrolled in EPAD, we intend to communicate with them in a frequent basis reminding them of the EPAD goals and asking them about their current condition and needs. We will also continue to inform them about the usefulness of spreading the news to other potential participants they may know.

Pictured (from left to right): Eirini Mamalaki, Eva Danasi, Nikolaos Scarmeas, Faidra Kalligerou and Dora Brikou. 

 

EPAD update

We currently have 28 sites across Europe enrolling and almost 2,000 research participants screened. Congratulations to the site Sheffield (UK) for screening their first research participants in November. We are pleased that this site became the latest addition to the EPAD family.

We hope that you will share our positive assessment of the continuing progress of this exciting research collaboration. Stay tuned for more news next year. EPAD thanks you all for the hard work within 2019 and wishes you Merry Christmas and a very happy New Year to all of you and your families!

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Data from AMYPAD PNHS is now available on the AD Workbench
2023-07-04
New paper showing Eigenvector centrality (EC) alterations in the pre-dementia stages of Alzheimer’s disease
2023-03-28
Analysis of multiple steroids in saliva in the EPAD study
2023-03-02
Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
2023-01-16
Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
2022-12-09
Bruno Steinkraus
Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
2022-11-25
Latest News
  • Data from AMYPAD PNHS is now available on the AD Workbench
    2023-07-04
  • New paper showing Eigenvector centrality (EC) alterations in the pre-dementia stages of Alzheimer’s disease
    2023-03-28
  • Analysis of multiple steroids in saliva in the EPAD study
    2023-03-02
  • Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
    2023-01-16
  • Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
    2022-12-09
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Workstream Progress
Workstream 120%
Workstream 232%
Workstream 310%
Workstream 446%
Contact us

Submitclear

Recent Posts
  • Data from AMYPAD PNHS is now available on the AD Workbench
  • New paper showing Eigenvector centrality (EC) alterations in the pre-dementia stages of Alzheimer’s disease
  • Analysis of multiple steroids in saliva in the EPAD study
  • Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
  • Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
Recent Comments
  • The EPAD genomic data is now available on the Alzheimer’s Disease Workbench on The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
  • ADDI celebrates one year of achievements – Neuronet on ADDI celebrates one year of achievements
  • EPAD dataset is now available on the Alzheimer’s Disease Workbench on The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
  • The final EPAD dataset is now available to the entire research community on The final EPAD dataset is now available to the entire research community
  • The ERC has awarded an ERC grant to identify age-related human blood factors as a therapeutic target for Alzheimer’s disease – Neuronet on New ERC starting grant to identify age-related human blood factors as a therapeutic target for Alzheimer’s disease
Archives
  • July 2023
  • March 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • January 2022
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • November 2020
  • October 2020
  • September 2020
  • July 2020
  • June 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • June 2015
  • May 2015
  • April 2015
Categories
  • EPAD Academy
  • News
Meta
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT